Is This Beaten Down Biotech a Bad News Buy?

Affecting one in 3,000 to 5,000 males worldwide, Duchenne muscular dystrophy (DMD) causes progressively worsening muscle weakness that eventually requires a wheelchair for most patients by age 11. Even worse, heart and lung complications often lead to mortality before age 30. Fortunately, Sarepta Therapeutics (NASDAQ: SRPT) has three approved RNAi therapies that can treat approximately 30% of the DMD population, and it's working on potentially curative gene therapies.

In the second quarter, the rare disease biotech raised full-year revenue guidance to between $565 million and $575 million, up from a prior range of $537 million to $547 million. Even more impressive than those 25% year-over-year revenue gains is its growth streak. After Sarepta's preliminary announcement of third-quarter results last week, the upcoming earnings report will mark an enviable 20th consecutive quarter of revenue growth.

Continue reading

Source Fool.com